Literature DB >> 8545283

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.

B Tjoa1, A Boynton, G Kenny, H Ragde, S L Misrock, G Murphy.   

Abstract

Dendritic cells (DCs) are "professional" antigen-presenting cells capable of stimulating T-cell proliferation and cytotoxicity when loaded with and presenting specific antigens, including tumor antigens. We demonstrated the stimulation of an autologous cytotoxic T-cell response elicited by DC loaded with autologous tumor cell lysate derived from primary prostate tumor. A candidate tumor antigen is prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer patients. We identified a HLA-A2 motif in PSMA, isolated patient DC, loaded peptide into DC, and stimulated autologous T cells to proliferate. The ability to use DC for presentation of either tumor or peptide antigen in an HLA-restricted fashion in order to stimulate T-cell proliferation and cytotoxicity demonstrates the potential of this technology for development of a prostate cancer vaccine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8545283     DOI: 10.1002/(SICI)1097-0045(199601)28:1<65::AID-PROS9>3.0.CO;2-N

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  15 in total

1.  Vaccine-based immunotherapy for prostate cancer.

Authors:  S F Shariat; F Sadeghi; K M Slawin
Journal:  Rev Urol       Date:  2000

2.  Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.

Authors:  Nirali N Shah; David M Loeb; Hahn Khuu; David Stroncek; Tolu Ariyo; Mark Raffeld; Cindy Delbrook; Crystal L Mackall; Alan S Wayne; Terry J Fry
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

Review 3.  Immunotherapy II: Antigens, receptors and costimulation.

Authors:  P F Searle; L S Young
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 4.  Role of dendritic cells in immunopathogenesis of human immunodeficiency virus infection.

Authors:  D Weissman; A S Fauci
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 5.  Prospects for vaccination in prostate cancer.

Authors:  M J Perry; D Hroulda; A G Dalgleish
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

6.  Aptamer-conjugated nanoparticles for cancer cell detection.

Authors:  Colin D Medley; Suwussa Bamrungsap; Weihong Tan; Joshua E Smith
Journal:  Anal Chem       Date:  2011-01-10       Impact factor: 6.986

Review 7.  Dendritic cell-based immunotherapy for prostate cancer.

Authors:  Hanka Jähnisch; Susanne Füssel; Andrea Kiessling; Rebekka Wehner; Stefan Zastrow; Michael Bachmann; Ernst Peter Rieber; Manfred P Wirth; Marc Schmitz
Journal:  Clin Dev Immunol       Date:  2010-11-04

8.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

Authors:  Philip M Arlen; James L Gulley; Catherine Parker; Lisa Skarupa; Mary Pazdur; Dennis Panicali; Patricia Beetham; Kwong Y Tsang; Douglas W Grosenbach; Jarett Feldman; Seth M Steinberg; Elizabeth Jones; Clara Chen; Jennifer Marte; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

9.  Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis.

Authors:  Paulus Tsui; Marvin Rubenstein; Patrick Guinan
Journal:  J Biomed Biotechnol       Date:  2005

10.  Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.

Authors:  A Kiessling; S Stevanovic; S Füssel; B Weigle; M A Rieger; A Temme; E P Rieber; M Schmitz
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.